Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;5(3):169-181.
doi: 10.1016/j.jpha.2014.12.002. Epub 2015 Jan 31.

Quality evaluation of synthetic quorum sensing peptides used in R&D

Frederick Verbeke  1 , Evelien Wynendaele  1 , Sarah Braet  1 , Matthias D'Hondt  1 , Bart De Spiegeleer  1
Affiliations

Quality evaluation of synthetic quorum sensing peptides used in R&D

Frederick Verbeke et al. J Pharm Anal. 2015 Jun.

Abstract

Peptides are becoming an important class of molecules in the pharmaceutical field. Closely related peptide-impurities in peptides are inherent to the synthesis approach and have demonstrated to potentially mask biomedical experimental results. Quorum sensing peptides are attracting high interest in R&D and therefore a representative set of quorum sensing peptides, with a requested purity of at least 95.0%, was evaluated for their purity and nature of related impurities. In-house quality control (QC) revealed a large discrepancy between the purity levels as stated on the supplier׳s certificate of analysis and our QC results. By using our QC analysis flowchart, we demonstrated that only 44.0% of the peptides met the required purity. The main compound of one sample was even found to have a different structure compared to the desired peptide. We also found that the majority of the related impurities were lacking amino acid(s) in the desired peptide sequence. Relying on the certificates of analysis as provided by the supplier might have serious consequences for peptide research, and peptide-researchers should implement and maintain a thorough in-house QC.

Keywords: Impurity profiling; Quality; Quorum sensing peptides.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(U)HPLC column flow chart for quorum sensing peptides analysis.
Fig. 2
Fig. 2
Purity levels of quorum sensing peptides determined by in-house QC.
Fig. 3
Fig. 3
The in-house QC control shows a distinct difference in peptide purity. (A) Chromatogram of supplier; Kromasil C18-5 (250 mm×4.6 mm, 5 µm), quantification at 220 nm; (B) chromatogram of in-house QC; Vydac Everest C18 column (250 mm×4.6 mm, 5 µm), quantification at 210 nm.
Fig. 4
Fig. 4
TIC and UV chromatogram (A), MS1 (B) and MS2 (C) spectra of the related impurity C1VFSLFKKC9N (disulfide bond between C1 and C9) of peptide ID25 at a retention time of 23.47 min with appointed isotopic mass patterns and b- and y-fragmentation are allocated.
Fig. 5
Fig. 5
TIC and UV chromatogram (A), MS1 (B) and MS2 (C) spectra of the related impurity LPFE(methyl)F of peptide ID134 at a retention time of 29.75 min with appointed isotopic mass patterns and b- and y-fragment allocation.
Fig. 6
Fig. 6
TIC and UV chromatogram (A), MS1 (B) and MS2 (C) spectra of the related impurity TIPKY of peptide ID82 at a retention time of 9.59 min with appointed isotopic mass patterns and b- and y-fragment allocation.
Fig. 7
Fig. 7
TIC and UV chromatogram (A), MS1 (B) and MS2 (C) spectra of the related impurity ILSGAPCIPWW of peptide ID121 at a retention time of 35.70 min with appointed isotopic mass patterns and b- and y-fragment allocation.
Fig. 8
Fig. 8
TIC and UV chromatogram (A), MS1 (B) and MS2 (C) spectra of the related impurity ILSGAPCIPPPP of peptide ID121 at a retention time of 33.55 min with appointed isotopic mass patterns and b- and y-fragment allocation.
Fig. 9
Fig. 9
Types of related peptide impurities found in the 61 experimentally determined sequences.
See this image and copyright information in PMC

References

    1. Craik D., Fairlie D., Liras S. The future of peptide-based drugs. Chem. Biol. Drug Des. 2013;81:136–147. - PubMed
    1. Berggren R., Moller M., Moss R. Outlook for the next 5 years in drug innovation. Nat. Rev. Drug Discov. 2012;11:435–436. - PubMed
    1. Van Arnum P. Peptides gain traction in drug development. Pharm. Technol. 2012;36:42–43.
    1. Albericio F., Kruger H. Therapeutic peptides. Future Med. Chem. 2012;4:1527–1531. - PubMed
    1. Danho W., Swistok J., Khan W. Peptides for Youth. In: Del Valle S., Escher E., Lubell W., editors. Proceedings of the 20th American Peptide Symposium. Springer Sciences and Business Media; NewYork, NY, USA: 2009. pp. 467–468.

LinkOut - more resources